Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial

Arthritis and Rheumatism

Volumn 54, Issue 7, 2006, Pages 2136-2146

  Van Der Heijde, Désirée ^a   Kivitz, Alan ^b   Schiff, Michael H ^c   Sieper, Joachim ^d   Dijkmans, Ben A C ^e   Braun, Jürgen ^f   Dougados, Maxime ^g   Reveille, John D ^h   Wong, Robert L ⁱ   Kupper, Hartmut ^j   Davis Jr , John C ^k  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Altoona Center for Clinical Research   (United States)

^c CLINICAL RESEARCH UNIT   (United States)

^d FREIE UNIVERSITÄT BERLIN   (Germany)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f Rheumatology Medical Centre Ruhrgebiet   (Germany)

^g University of Paris ^*  (France)

^h UNIVERSITY OF TEXAS   (United States)

ⁱ ABBOTT LABORATORIES   (United States)

^j ABBOTT GMBH AND CO KG   (Germany)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HEMOGLOBIN; HLA B27 ANTIGEN; HYDROXYCHLOROQUINE; LIVER ENZYME; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; RIFAMPICIN; SALAZOSULFAPYRIDINE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR;

ADULT; ALLELE; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; HEAD INJURY; HEADACHE; HUMAN; HYPERGAMMAGLOBULINEMIA; INFECTION; INJECTION SITE REACTION; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONCARDIAC CHEST PAIN; OUTCOME ASSESSMENT; PATELLA FRACTURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHINOPHARYNGITIS; SPINE MOBILITY; SPINE RADIOGRAPHY; THORAX PAIN; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URTICARIA;

ADULT; ANTIBODIES, MONOCLONAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33745894976     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21913     Document Type: Article

References (48)

1. Maksymowych WP. Ankylosing spondylitis. In: Rakel RE, Bope ET, editors. Conn's Current Therapy. Philadelphia: WB Saunders; 2001. p. 1021-3.
2. Akkoc N, Khan MA. Overestimation of the prevalence of ankylosing spondylitis in the Berlin study: comment on the article by Braun et al [letter]. Arthritis Rheum 2005;52:4048-9.
3. Ward MM. Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis Rheum 2002;46:223-31.
4. Boonen A, van der Heijde D, Landewe R, Spoorenberg A, Schouten H, Rutten-van Molken M, et al. Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis 2002;61:429-37.
5. Boonen A, van der Heijde D, Landewe R, Guillemin F, Rutten-van Molken M, Dougados M, et al. Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries. Ann Rheum Dis 2003;62:732-40.
6. Davis JC, van der Heijde D, Dougados M, Woolley JM. Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy. Arthritis Rheum 2005;53:494-501.
7. Heiberg MS, Nordvag BY, Mikkelsen K, Rodevand E, Kaufmann C, Mowinckel P, et al. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study. Arthritis Rheum 2005;52:2506-12.
8. Barkham N, Kong KO, Tennant A, Fraser A, Hensor E, Keenan AM, et al. The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis. Rheumatology (Oxford) 2005;44:1277-81.
9. Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995;38:499-505.
10. Wanders A, van der Heijde D, Landewe R, Behier JM, Calin A, Olivieri I, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005;52:1756-65.
11. Zochling J, van der Heijde D, Dougados M, Braun J. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2006;65:423-32.
12. Van den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Mielants F, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002;46:755-65.
13. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93.
14. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. N Engl J Med 2002;346:1349-56.
15. Davis JC Jr, van der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al, for the Enbrel Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-6.
16. Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004;63:1594-600.
17. Van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al, for the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91.
18. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, et al. Two-year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 2005;64:229-34.
19. Braun J, Baraliakos X, Brandt J, Listing J, Zink A, Alten R, et al. Persistent clinical response to the anti-TNF-α antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) 2005;44:670-6.
20. Davis JC, van der Heijde D, Braun J, Dougados M, Cush J, Clegg D, et al. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 2005;64:1557-62.
21. Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al. Adalimumab, a fully human anti tumor necrosis factor-α monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30:2563-71.
22. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial [published erratum appears in Arthritis Rheum 2003;48:855]. Arthritis Rheum 2003;48:35-45.
23. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11.
24. Van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508-16.
25. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al, for the ADEPT Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89.
26. Lipsky PE, van der Heijde DM, St. Clair EW. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;34:1594-602.
27. Moreland LW, Cohen SB, Baumgartner SW, Tindall EA, Bulpitt K, Martin R, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001;28:1238-44.
28. Schiff M, van de Putte LB, Breedveld FC, Kupper H, Fischkoff S, Chartash E. Rates of infection in adalimumab rheumatoid arthritis clinical trials [abstract]. Ann Rheum Dis 2003;62 Suppl I:184.
29. Schiff MH, Gelhorn AJ, Chartash E, Fischkoff SA. Malignancies in rheumatoid arthritis (RA) clinical trials with adalimumab (HUMIRA) [abstract]. Arthritis Rheum 2003;48 Suppl 9:S700.
30. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
31. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing Spondylitis Assessment Group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86.
32. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
33. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
34. Van der Heijde D, Dougados M, Davis J, Weisman MH, Maksymowych W, Braun J, et al. Assessment in Ankylosing Spondylitis International Working Group/Spondylitis Association of America recommendations for conducting clinical trials in ankylosing spondylitis. Arthritis Rheum 2005;52:386-94.
35. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS Metrology Index. J Rheumatol 1994;21:1694-8.
36. Moll JM, Wright V. An objective clinical study of chest expansion. Ann Rheum Dis 1972;31:1-8.
37. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, Landewe R, van der Tempel H, Mielants H, et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003;62:127-32.
38. Jones SD, Steiner A, Garrett SL, Calin A. The Bath Ankylosing Spondylitis Patient Global Score (BAS-G). Br J Rheumatol 1996;35:66-71.
39. Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J. Development and preselection criteria for short-term improvement after anti-TNFα treatment in ankylosing spondylitis. Ann Rheum Dis 2004;63:1438-44.
40. Sieper J, Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, et al. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. Rheumatology (Oxford) 2005;44:1525-30.
41. Baraliakos X, Davis J, Tsuji W, Braun J. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor α receptor fusion protein etanercept. Arthritis Rheum 2005;52:1216-23.
42. Baraliakos X, Listing J, Rudwaleit M, Brandt J, Sieper J, Braun J. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis 2005;64:1462-6.
43. Baraliakos X, Listing J, Brandt J, Rudwaleit M, Sieper J, Braun J. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 2005;7:R439-44.
44. Antoni CE, Kavanaugh A, Kirkham B, Tutuneu Z, Burmester GR, Schneider U, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum 2005;52:1227-36.
45. Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003;139:1627-32.
46. Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005;52:2447-51.
47. Hanauer SB. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: overview of randomized clinical studies. Rev Gastroenterol Disord 2004;4 Suppl 3:S18-24.
48. Wells AF, Kupper H, Fischkoff S, Chartash E. Injection-site reactions in adalimumab rheumatoid arthritis (RA) pivotal clinical trials [abstract]. Ann Rheum Dis 2003;62 Suppl 1:411.